Browse All

Current Filters

CLEAR FILTER x

TITLE

Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results from the Phase 3 ASCLEPIOS I/II Trials

Author:Freeman, Jason   Delgado, Silvia   Alvarez, Enrique   Thouvenot, Eric   Okai, Annette   Bhatt, Alit   Wei, Wenjia   Ziemssen, Tjalf   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.006  

Author Institution:Novartis Pharmaceuticals, USCDMA , East Hanover , NJ  University of Miami Miller School of Medicine, Miami, FL  University of Colorado School of Medicine, Aurora, CO  CHU Nîmes, Univ Montpellier, Nîmes, France  North Texas Institute of Neurology and Headache, Plano, TX  Novartis Healthcare Pvt. Ltd., Hyderabad, India  Novartis Pharma AG, Basel, Switzerland  University Clinic Carl-Gustav Carus, Dresden, Germany  

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis

Author:Bar-Or, Amit   Wiendl, Heinz   De Seze, Jerome   Correale, Jorge   Cross, Anne   Derfuss, Tobias   Selmaj, Krzysztof   Winthrop, Kevin   Giacomini, Paul   Sacca, Francesco   Hu, Xixi   Sullivan, Roseanne   Jehl, Valentine   Boer, Ibolya   Bhatt, Alit   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.007  

Author Institution:Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  University of Muenster, Muenster, Germany  University Hospital of Strasbourg, Strasbourg, France  Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina  Washington University School of Medicine, Clayton, MO  Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland  Center for Neurology, Lodz, Lodz, Poland  Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada  NSRO Department, University “Federico II” of Naples, Naples, Italy  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare Pvt. Ltd., Hyderabad, India  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA